ARCUS BIOSCIENCES INC reports a Return on Equity (ROE) of -70.42%.

What is RCUS's dividend yield?

ARCUS BIOSCIENCES INC offers a dividend yield of 0.00%.

What is RCUS's Deepscope Quality Score?

Deepscope rates RCUS's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy RCUS?

Deepscope's AI Timing Score for RCUS is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does RCUS belong to?

ARCUS BIOSCIENCES INC is classified under the Healthcare >> Biotechnology sector on the NYSE exchange.

Cổ phiếu RCUS (NYSE) | ARCUS BIOSCIENCES INC

Stock Check Daily update data at 9:30 AM
(Price: 2026-06-10 | FS: 2026-03-31)

RCUS

ARCUS BIOSCIENCES INC

US:NYSE STOCK Healthcare >> Biotechnology News 80

USD 22.12

-1.52 (-6.43%) Day Change

Watchlist Portfolio Compare Chart

0.19

D/E

-70.4%

ROE

-37.0%

ROA

0.00%

Div Yield

ARCUS BIOSCIENCES INC
TYPE: STOCK
MARKET: NYSE

Compare Watchlist Myport

USD 22.12 Price -1.52 (-6.43%) Day Change	NEWS SCORE: 80

RCUS Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 31) và Thời điểm mua ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
Lịch sử ROE tương đối thấp
ROE đang giảm đáng kể
Tăng trưởng ROA dưới mức tiêu chí của chúng tôi trong năm vừa qua
Tăng trưởng ROA hiện tại đang dưới mức tiêu chí của chúng tôi.
Biên lợi nhuận ròng tương đối thấp.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
Lịch sử Biên lợi nhuận ròng tương đối thấp.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Lorem ipsum dolor sit amet

Unlock timing signals and detailed reasons

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Không tốt lắm , ...

Yếu tố Chất lượng

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	80
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	22.12
PBV / Sector	5.67 / 4.79
Earning Per Share	-2.75

PE / Sector	N/A / 17.89
PEG or PE/Growth / Sector	N/A / 0.56
Average 1M Daily Value	21.18 M GREAT
Average 1W Daily Value	23.24 M GREAT

Yếu tố Kỹ thuật

14%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Sức khỏe tài chính

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Khả năng kiếm lợi nhuận

52%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-156.36 / 468.85
NPM Average (%) / Sector	-181.95 / -1,531.69
NPM Change Average (%) / Sector	-2.11 / 5,028.65
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-37.01 / 31.69
ROA Average (%) / Sector	-28.10 / -353.18
ROA Change Average (%) / Sector	18.59 / 5,214.65 GOOD
ROE (%) / Sector	-70.42 / 10.58
ROE Average (%) / Sector	-58.36 / 27.64
ROE Change Average (%) / Sector	18.27 / 2,048.88 GOOD
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Lợi tức cho nhà đầu tư

Dividend (%) / Sector	N/A / 0.05
Dividend Average (%) / Sector	N/A / 16.49
Dividend Change Average (%) / Sector	N/A / 4.77

Chi tiết đăng ký

Analyze Date	2026-06-11 09:54:20
Symbol	RCUS
Name	ARCUS BIOSCIENCES INC
Sector	Healthcare >> Biotechnology
Market	NYSE
Listed Shares	125.77 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	2,973.28 / 8,963.32

Tin tức, Dự báo ước tính

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 3928 Point Eden Way, Hayward, CA, United States, 94545

Phone: 510 694 6200

Website: https://arcusbio.com

Employees: 601

Sector: Healthcare >> Biotechnology

Description: Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.